DEVICE AND METHOD FOR DETERMINING ANALYTE LEVELS

• US 20140128701A1
• Filed: 12/30/2013
• Published: 05/08/2014
• Est. Priority Date: 03/04/1997
• Status: Active Grant

• Current Assignee: DexCom Incorporated
• Original Assignee: DexCom Incorporated
• Inventors: Shults, Mark C., Updike, Stuart J., Rhodes, Rathbun K.
• Granted Patent: US 9,339,223 B2
• Time in Patent Office: Days
• US Class Current: 600/347
• CPC Class Codes: A61B 5/0004 characterised by the type of physiological signal transmitted
• CPC Class Codes: A61B 5/14532 for measuring glucose, e.g. by tissue impedance measurement
• CPC Class Codes: A61B 5/14865 invasive, e.g. introduced into the body by a catheter or needle or using implanted sensors
• CPC Class Codes: A61B 5/1495 Calibrating or testing of in-vivo probes
• CPC Class Codes: C12Q 1/006 for glucose

Abstract

Devices and methods for determining analyte levels are described. The devices and methods allow for the implantation of analyte-monitoring devices, such as glucose monitoring devices, that result in the delivery of a dependable flow of blood to deliver sample to the implanted device. The devices comprise a unique microarchitectural arrangement in the sensor region that allows accurate data to be obtained over long periods of time.

Claims

1-20. -20. (canceled)

21. A device for measuring a glucose concentration in a host, the device comprising:

an implantable sensor operably connected to an electronic circuit and configured to continuously measure a signal indicative of a glucose concentration in a host for a period of time; and

a membrane located over at least a portion of the sensor, wherein the membrane is configured to control a flux of oxygen and glucose, wherein the membrane comprises a product of a reaction of a compound comprising an isocyanate group with a compound comprising a hydroxyl group and/or a compound comprising an amine group;

wherein the device during in vitro testing is capable of exhibiting, at a glucose concentration of 400 mg/dL, no more than a 10% drop in sensor output in response to a change of dissolved oxygen concentration from a pO₂ of 150 mm Hg to 30 mm Hg.

22. The system of claim 21, wherein the product is polyurethane.

23. The system of claim 21, wherein the product is polyurea.

24. The system of claim 21, wherein the product is a polyurethaneurea copolymer.

25. The system of claim 21, wherein the membrane comprises a layer that is permeable to hydrogen peroxide, wherein the layer restricts passage of ascorbic acid therethrough.